Biogen Idec Inc (BIIB.OQ)
220.22USD
4:00pm EDT
$2.09 (+0.96%)
$218.13
$218.82
$221.53
$218.03
365,053
465,996
$242.52
$134.00
About
Overall
| Beta: | 0.90 |
| Market Cap (Mil.): | $51,843.30 |
| Shares Outstanding (Mil.): | 237.67 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 32.34 | 47.13 | 37.76 |
| EPS (TTM): | 6.74 | -- | -- |
| ROI: | 18.74 | -2.58 | 18.76 |
| ROE: | 22.70 | -2.66 | 19.59 |
Biogen's new MS drug shines in market debut
- Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera had surpassed Wall Street's most bullish forecasts, raising expectations that it will eventually become the dominant oral MS treatment.
UPDATE 3-Biogen's new MS drug shines in market debut
July 25 - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera had surpassed Wall Street's most bullish forecasts, raising expectations that it will eventually become the dominant oral MS treatment.
Biogen new MS drug sales shine in first quarter on market
July 25 - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera that blew away initial Wall Street estimates, confirming an extremely strong launch for a medicine expected to dominate the market for oral treatments.
Biogen investigates death of patient who took MS drug Tecfidera
July 22 - Biogen Idec Inc is investigating the death of a patient who had taken its new multiple sclerosis drug, Tecfidera, the company said on Monday.
Divisive Elan boss Martin faces ownership showdown
DUBLIN/NEW YORK - When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the troubled company and sell it.
Biogen delays MS drug's EU launch to secure market exclusivity
May 30 - Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer period.
Biogen profit beats estimates, raises 2013 forecast
- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.
UPDATE 3-Biogen profit beats estimates, raises 2013 forecast
April 25 - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.
BRIEF-Biogen sees Tecfidera becoming leading oral drug MS drug
April 25 - Biogen Idec Inc : * Says believes tecfidera will become leading oral drug in ms market
Biogen profit beats estimates, raises 2013 forecast
- Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecast.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Genmab A/S (GEN.CO) | kr.161.40 | -0.60 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| Amgen, Inc. (AMGN.OQ) | $109.45 | +1.16 |
| UCB SA (UCB.BR) | €44.24 | +0.91 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

